Tags

Type your tag names separated by a space and hit enter

[Cardiomyopathy in liver cirrhosis--an undiagnosed entity?].
Rev Med Chir Soc Med Nat Iasi. 2010 Apr-Jun; 114(2):319-26.RM

Abstract

Cirrhotic cardiomyopathy is a condition recently known in liver cirrhosis consisting of systolic dysfunction to stress factors, diastolic dysfunction and electrophysiological abnormalities in the absence of cardiac disease. The prevalence of cirrhotic cardiomyopathy remains unknown until now. It can be diagnosed by using a combination of electrocardiograph, 2-dimensional echocardiography, and various serum markers (brain natriuretic factor--BNP, proBNP, TnI). Pathogenic mechanisms underlying cirrhotic cardiomyopathy development include abnormal signaling betaadrenergic, cardiomyocites membrane fluidity changes, interstitial fibrosis, myocardial hypertrophy, altered transmembrane ion channels as intervention with negative inotropic effect of different substances whose concentration is increased in cirrhosis. Major stresses on the cardiovasculary system such as liver transplantations, infections, insertion of transjugular portosystemic stent-shunt (TIPSS) have been demonstrated to put in evidence the presence of cirrhotic cardiomyopathy. Heart failure is a significant cause of mortality after liver transplantation but the improvement of liver function determines cardiac abnormalities reversal. Current management recommendations include empirical, nonspecific and mainly supportive measures, no specific treatment can be recommended, and cardiac failure should be treated as in non-cirrhotic patients with sodium restriction, diuretics, and oxygen therapy when necessary. The exact prognosis remains unclear. The extent of cirrhotic cardiomyopathy generally correlates to the degree of liver insufficiency. Reversibility is possible (either pharmacological or after liver transplantation), but further studies are needed.

Authors+Show Affiliations

Burcă P
Universitatea de Medicină şi Farmacie Gr.T. Popa, Facultatea de Medicinaă, Institutul de Gastroenterologie şi Hepatologie Iaşi.
Mihai B
No affiliation info available
Mihai C
No affiliation info available
Drug VL
No affiliation info available
Dranga M
No affiliation info available
Lăcătuşu C
No affiliation info available
Prelipcean CC
No affiliation info available

MeSH

BiomarkersCardiomyopathiesDiagnosis, DifferentialDiureticsElectrocardiographyHeart Failure, DiastolicHeart Failure, SystolicHumansLiver CirrhosisNatriuretic AgentsNatriuretic Peptide, BrainOxygen Inhalation TherapyPrognosisRisk FactorsTroponin I

Pub Type(s)

English Abstract
Journal Article

Language

rum

PubMed ID

20700961

Citation

Burcă, Paula, et al. "[Cardiomyopathy in Liver Cirrhosis--an Undiagnosed Entity?]." Revista Medico-chirurgicala a Societatii De Medici Si Naturalisti Din Iasi, vol. 114, no. 2, 2010, pp. 319-26.
Burcă P, Mihai B, Mihai C, et al. [Cardiomyopathy in liver cirrhosis--an undiagnosed entity?]. Rev Med Chir Soc Med Nat Iasi. 2010;114(2):319-26.
Burcă, P., Mihai, B., Mihai, C., Drug, V. L., Dranga, M., Lăcătuşu, C., & Prelipcean, C. C. (2010). [Cardiomyopathy in liver cirrhosis--an undiagnosed entity?]. Revista Medico-chirurgicala a Societatii De Medici Si Naturalisti Din Iasi, 114(2), 319-26.
Burcă P, et al. [Cardiomyopathy in Liver Cirrhosis--an Undiagnosed Entity?]. Rev Med Chir Soc Med Nat Iasi. 2010 Apr-Jun;114(2):319-26. PubMed PMID: 20700961.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Cardiomyopathy in liver cirrhosis--an undiagnosed entity?]. AU - Burcă,Paula, AU - Mihai,B, AU - Mihai,Cătălina, AU - Drug,V L, AU - Dranga,Mihaela, AU - Lăcătuşu,Cristina, AU - Prelipcean,Cristina Cijevschi, PY - 2010/8/13/entrez PY - 2010/8/13/pubmed PY - 2010/9/30/medline SP - 319 EP - 26 JF - Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi JO - Rev Med Chir Soc Med Nat Iasi VL - 114 IS - 2 N2 - Cirrhotic cardiomyopathy is a condition recently known in liver cirrhosis consisting of systolic dysfunction to stress factors, diastolic dysfunction and electrophysiological abnormalities in the absence of cardiac disease. The prevalence of cirrhotic cardiomyopathy remains unknown until now. It can be diagnosed by using a combination of electrocardiograph, 2-dimensional echocardiography, and various serum markers (brain natriuretic factor--BNP, proBNP, TnI). Pathogenic mechanisms underlying cirrhotic cardiomyopathy development include abnormal signaling betaadrenergic, cardiomyocites membrane fluidity changes, interstitial fibrosis, myocardial hypertrophy, altered transmembrane ion channels as intervention with negative inotropic effect of different substances whose concentration is increased in cirrhosis. Major stresses on the cardiovasculary system such as liver transplantations, infections, insertion of transjugular portosystemic stent-shunt (TIPSS) have been demonstrated to put in evidence the presence of cirrhotic cardiomyopathy. Heart failure is a significant cause of mortality after liver transplantation but the improvement of liver function determines cardiac abnormalities reversal. Current management recommendations include empirical, nonspecific and mainly supportive measures, no specific treatment can be recommended, and cardiac failure should be treated as in non-cirrhotic patients with sodium restriction, diuretics, and oxygen therapy when necessary. The exact prognosis remains unclear. The extent of cirrhotic cardiomyopathy generally correlates to the degree of liver insufficiency. Reversibility is possible (either pharmacological or after liver transplantation), but further studies are needed. SN - 0048-7848 UR - https://www.unboundmedicine.com/medline/citation/20700961/[Cardiomyopathy_in_liver_cirrhosis__an_undiagnosed_entity]_ L2 - https://www.diseaseinfosearch.org/result/1090 DB - PRIME DP - Unbound Medicine ER -